Mylan Duragesic Generic Launches Into “Irrationally” Priced Market

Mylan's ability to recoup profits lost to early competitive pricing on Duragesic generics could depend on the timing of other ANDA approvals and Johnson & Johnson's ability to supply an "authorized" generic, CEO Robert Coury said Feb. 3